Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Lidocain, ATC N01BB02 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. Verlängerungsoption 1x12 Monate)

Section 130a(8) SGB V allows health insurance funds and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of the statutory health insurance funds. In view of the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-specific, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned substance lidocaine, ATC N01BB02, the DAK-Gesundheit intends to conclude medicine rebate contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine rebate contracts. A rebate contract under the approval model for the aforementioned substance will come into force for the first time on 01.09.2026 and will end on 31.08.2028 (plus extension option 1x12 months). It will automatically end, regardless of this, with the entry into force of the exclusive contract.